Biotech Business - June 11, 2020
BioInvent completes directed share issue of 487 million SEK
The Board of Directors of BioInvent International has resolved to issue a directed share issue to Swedish and international institutional investors. Investors in the Directed Share Issue are a number of Swedish and international investors, including new investors such as HBM Healthcare Investments Ltd. (“HBM), Swedbank Robur Medica and Invus Public Equities, L.P. as well […]
Biotech Business - May 15, 2020
BioInvent presents promising results and expands anti-TNFR2 program
BioInvent International has announced the presentation of promising new data on its anti-tumor necrosis factor receptor 2 (TNFR2) program at the American Association for Cancer Research (AACR) Annual Meeting. The results shows that TNFR2 is particularly upregulated on tumor-associated regulatory T cells (Tregs) and has been shown to be important for their expansion and survival. […]
Clinical Trials - June 18, 2019
New clinical data from BioInvent
The company has announced the publication of the first data from two parallel Phase l/lla clinical trials of its lead product candidate BI-1206 as single agent and/or in combination with rituximab, currently being conducting in the UK and the US/EU respectively. In the UK trial, 10 patients have received single agent therapy with up to […]
Biotech Business - December 7, 2017
BioInvent and Transgene collaborate
BioInvent International and Transgene have entered a collaboration to co-develop next generation oncolytic virus (OV) candidates encoding an anti-CTLA-4 antibody sequence – potentially with additional transgenes – capable of treating multiple solid tumors. Under the terms of the agreement Transgene will contribute both its OV design and engineering expertise as well as its engineered Vaccinia virus, derived […]
In a new job - October 25, 2017
The CEO of BioInvent resigns
BioInvent International announces that Michael Oredsson will resign as CEO of BioInvent 31 December 2017. Michael took office as CEO of BioInvent in 2013 to restructure the company and refocus on oncology. Now, both the board and Michael believe that it is a good time for a change in leadership, as the company is transitioning […]
Biotech Business - October 24, 2017
BioInvent plans to expand therapeutic potential
BioInvent announces its plans to expand the therapeutic potential of its lead antibody BI-1206. The current development program will be expanded with an open, single-arm Phase I/IIa clinical study to evaluate BI-1206 in combination with rituximab. This study is estimated to enrol approximately twenty patients with relapsed or refractory Non-Hodgkin Lymphoma (NHL), and will include […]
